Barclays
INBX icon

Barclays’s Inhibrx INBX Stock Holding History

Barclays’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$392K Buy
3,918
+1,571
+67% +$157K ﹤0.01% 3601
2026
Q2 		$222K Buy
2,347
+680
+41% +$68.1K ﹤0.01% 3633
2026
Q1 		$112K Sell
1,667
-20,212
-92% -$1.5M ﹤0.01% 3976
2025
Q4 		$1.73M Buy
21,879
+8,411
+62% +$573K ﹤0.01% 3045
2025
Q3 		$454K Sell
13,468
-3,696
-22% -$91K ﹤0.01% 3867
2025
Q2 		$245K Buy
17,164
+3,881
+29% +$50.2K ﹤0.01% 4157
2025
Q1 		$186K Sell
13,283
-5,558
-29% -$75.5K ﹤0.01% 4086
2024
Q4 		$290K Buy
18,841
+2,786
+17% +$42.4K ﹤0.01% 4136
2024
Q3 		$251K Buy
16,055
+12,476
+349% +$175K ﹤0.01% 4182
2024
Q2 		$50.7K Buy
+3,579
New +$55.9K ﹤0.01% 4210

Other funds holding INBX

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays's INBX Position: Q3 2026 in Review

Barclays increased its Inhibrx (INBX) stake by 67% in Q3 2026, buying an estimated $157K and bringing the position to 3,918 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #3601.

Barclays first reported a position in INBX in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.73M in Q4 2025. 67 funds tracked by Wall St. Rank hold INBX as of Q3 2026.

  • Barclays held 3,918 shares of Inhibrx worth $392K as of Q3 2026.
  • Barclays bought 1,571 Inhibrx shares in Q3 2026, an estimated $157K.
  • Inhibrx made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3601 holding.
  • Barclays first reported a position in Inhibrx in Q2 2024 and has held it in 10 quarters since.
  • Barclays's Inhibrx position peaked at $1.73M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Inhibrx as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.